Sanofi Pasteur announced that the first doses of Fluzone (influenza vaccine) for the upcoming 2017–2018 influenza season have been shipped.
The Company has started to distribute initial orders for the upcoming flu season, and reports that broader shipment of the Fluzone portfolio will begin in early August to healthcare providers. The Fluzone vaccine product line includes Fluzone High-Dose, Fluzone Quadrivalent , and Fluzone Intradermal Quadrivalent.
Fluzone High-Dose is approved for use in patients aged ≥65 years; Fluzone Quadrivalent is a 4-strain influenza vaccine (2 A strains and 2 B strains) intended for use in patients ≥6 months; and Fluzone Intradermal Quadrivalent also provides 4-strain protection for patients aged 18–64 years.
The Fluzone vaccines should not be given to any individual with a severe allergic reaction to any vaccine component, including eggs, egg products, thimerosol, or to a previous dose of any flu vaccine.
The Centers for Disease Control and Prevention (CDC) recommends an annual influenza vaccination as soon as the product becomes available.
Fluzone High-Dose is available as a 0.5mL prefilled syringe in 10-count cartons. Fluzone Quadrivalent is available as 0.25mL and 0.5mL prefilled syringes in 10-count cartons. Fluzone Intradermal Quadrivalent is available as a 0.1mL single-dose prefilled microinjection system in 10-count cartons.
- Fluzone High-Dose vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016.
- Fluzone Quadrivalent vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016.
- Fluzone Intradermal Quadrivalent vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016.
This article originally appeared on MPR